Abstract:Objective: We assessed the role of glycogen synthase kinase-3 beta (GSK-3 beta) and kinin B2 receptor in mediating tissue kallikrein's protective effects against cardiac hypertrophy.Methods: We investigated the effect and mechanisms of tissue kallikrein using hypertrophic animal models of rats as well as mice deficient in kinin B1 or B2 receptor after aortic constriction (AC).Results: Intramyocardial delivery of adenovirus containing the human tissue kallikrein gene resulted in expression of recombinant kallikrein in rat myocardium. Kallikrein gene delivery improved cardiac function and reduced heart weight/body weight ratio and cardiomyocyte size without affecting mean arterial pressure 28 days after AC. Icatibant and adenovirus carrying a catalytically inactive GSK-3 beta mutant (Ad. GSK-3 beta-KM) abolished kallikrein's effects. Kallikrein treatment increased cardiac nitric oxide (NO) levels and reduced NAD(P)H oxidase activity and superoxide production. Furthermore, kallikrein reduced the phosphorylation of apoptosis signal-regulating kinase 1, mitogen-activated protein kinases (MAPKs), Akt, GSK-3 beta, and cAMP-response element binding (CREB) protein, and decreased nuclear factor-kappa B (NF-kappa B) activation in the myocardium. Ad.GSK-3 beta-KM abrogated kallikrein's actions on GSK-3 beta and CREB phosphorylation and NF-kappa B activation, whereas icatibant blocked all kallikrein's effects. The protective role of kinin B2 receptor in cardiac hypertrophy was further confirmed in kinin receptor knockout mice as heart weight/body weight ratio and cardiomyocyte size increased significantly in kinin B2 receptor knockout mice after AC compared to wild type and B1 receptor knockout mice.Conclusions: These findings indicate that tissue kallikrein, through kinin B2 receptor and GSK-3 beta signaling, protects against pressure overload-induced cardiomyocyte hypertrophy by increased NO formation and oxidative stress-induced Akt-GSK-3 beta-mediated signaling events, MAPK and NF-kappa B activation. (c) 2006 European Society of Cardiology. Published by Elsevier B.V.

Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.

Tissue Kallikrein and Kinin Infusion Rescues Failing Myocardium after Myocardial Infarction

Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation.

Tissue Kallikrein Promotes Neovascularization and Improves Cardiac Function by the Akt-glycogen Synthase Kinase-3Beta Pathway.

The effects of long term infusion tissue kallikrein and bradykinin on failing myocardium after myocardial infarction

Kallikrein/Kinin Protects Against Myocardial Apoptosis after Ischemia/Reperfusion Via Akt-Glycogen Synthase Kinase-3 and Akt-Bad·14-3-3 Signaling Pathways

Role of Kallistatin in Prevention of Cardiac Remodeling after Chronic Myocardial Infarction

TANK-binding Kinase 1 Alleviates Myocardial Ischemia/reperfusion Injury Through Regulating Apoptotic Pathway.

Novel Role of Kallistatin in Protection Against Myocardial Ischemia?Reperfusion Injury by Preventing Apoptosis and Inflammation

Tissue Kallikrein Protects Against Pressure Overload-Induced Cardiac Hypertrophy Through Kinin B2 Receptor and Glycogen Synthase Kinase-3Beta Activation.

Kallikrein Gene Transfer Protects Against Ischemic Stroke by Promoting Glial Cell Migration and Inhibiting Apoptosis.

Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis

Cardioprotection of Klotho Against Myocardial Infarction-Induced Heart Failure Through Inducing Autophagy.

Abstract 19689: Kdm3a Protects Myocardium from Ischemia/reperfusion Injury Through Targeting Akt-dependent Signaling Pathways

Cathepsin B Inhibition Attenuates Cardiac Dysfunction and Remodeling Following Myocardial Infarction by Inhibiting the NLRP3 Pathway.

The Tissue Kallikrein-Kinin System Protects Against Cardiovascular and Renal Diseases and Ischemic Stroke Independently of Blood Pressure Reduction

Cardioprotective Effects of a Selective c-Jun N-terminal Kinase Inhibitor in a Rat Model of Myocardial Infarction

Kallikrein–kinin in stroke, cardiovascular and renal disease

Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity.

Tissue Kallikrein supplementation in ischemic phase protects the neurovascular unit and attenuates reperfusion-induced injury in ischemic stroke

Cardiaprotective Effect of Crocetin by Attenuating Apoptosis in Isoproterenol Induced Myocardial Infarction Rat Model.